Data from Eli Lilly’s SURPASS-4 Trial of Tirzepatide in Adults with Type 2 Diabetes with Increased Cardiovascular Risk Published in The Lancet

Data from Eli Lilly’s SURPASS-4 Trial of Tirzepatide in Adults with Type 2 Diabetes with Increased Cardiovascular Risk Published in The Lancet

Eli Lilly announced detailed results from the SURPASS-4 clinical trial have been published in The Lancet. SURPASS-4 is the largest and longest clinical trial completed to date of the phase 3 program studying tirzepatide as a potential treatment for type 2 diabetes. In this trial, adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine. These improvements were maintained for up to two years.

The open-label global SURPASS-4 trial compared the safety and efficacy of three tirzepatide doses (5 mg, 10 mg and 15 mg) to titrated insulin glargine in 2,002 adults with type 2 diabetes with increased CV risk who were treated with between one and three oral antihyperglycemic medicines (metformin, a sulfonylurea or an SGLT-2 inhibitor). Of the total randomized patients, 1,819 (91%) completed the primary 52-week visit and 1,706 (85%) completed the study on treatment. The median study duration was 85 weeks and 202 participants (10%) completed two years.

Patients had a mean duration of 11.8 years with diabetes, recordin...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee